Impact of Cancer Treatment on Reproductive Health and Options for Fertility Preservation by Rodriguez-Wallberg, Kenny A.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 21
Impact of Cancer Treatment on Reproductive Health
and Options for Fertility Preservation
Kenny A. Rodriguez-Wallberg
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/55980
1. Introduction
1.1. Cancer in patients of reproductive age
Cancer is in general regarded as a disease of elderly people. Nevertheless, although age is the
most significant risk factor for cancer in both sexes, young adults and children may also
develop cancer diseases. Overall, men have a 45% risk of developing cancer at some time
during their lives. For women, this risk is a bit lower, approximately 37% [1] and thus, in many
cases, male and female cancer patients would be young and may not have been started building
their families at the time of diagnosis. In people younger than 39 years, the risk of cancer is of
about 1/72 for men and 1/51 for women. This risk increases with aging and between 40-59
years, 1/12 men and 1/11 women will develop cancer [1].
The majority of children, adolescents, and young adults diagnosed with cancer today will
become long-term survivors. One primary concern of cancer survivors will be the ability to
reproduce and have children. Detrimental effects on the reproductive system following cancer
treatment have shown to negatively affect quality of life[2], [3]. Large studies of women and
men with cancer have reported that the risk of infertility related to their treatments may be an
important issue for those who have not yet started or completed their family size [2], [4].
2. Cancer treatment modalities with impact in reproductive health
Cancer surgery may have impact in fertility by removing reproductive organs or damaging
structures needed for reproduction. Chemotherapy and radiotherapy have toxic effects on the
gonads and may in certain cases induce ovarian and testicular failure, affecting thus all aspects
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of reproductive health, including pubertal development, impairment of hormone production
and sexual function in adults. Effects of cancer biological therapy on gametes and reproductive
organs are not yet established.
3. Cancer surgery may cause infertility
Surgery is currently the most effective treatment for cancer and eventually up to 100% of
patients may be cured when complete removal of the tumor is achieved. Surgery may also be
indicated for cancer prophylaxis, such as the case of premalignant disease of the cervix in
female patients. In those very early stages of cervix cancer, the conization of a significant part
of the cervix, may offer to patients a complete disease-free survival. However, in case of loop
excisions, even if they are small, surgery of the cervix may induce subfertility by affecting the
normal functioning of the cervix and its glandular secretion. Infertility induced by those
interventions may be overcomed by using assisted reproductive technologies, such as treating
the patient with intrauterine insemination or performing In Vitro Fertilization, IVF.
Surgery may also affect future fertility if there is removal or damage of the reproductive organs.
In male patients, surgery for pelvic cancer such as for prostate, bladder or colon cancer may
damage nerves and affect potency or ejaculation. Further on, surgical adjuvant treatment by
removing the gonads may be indicated in female and male patients with hormone sensitive
tumors.
In case of large tumors, neo-adjuvant chemotherapy and radiation may be indicated as first
line treatment aiming to a reduction of tumor size and control of subclinical metastatic disease
before surgical treatment. Neo-adjuvant therapy is usually planned before surgery in female
patients with stage III breast cancer and young male cancer patients with bulky testicular
cancer.
3.1. Cancer surgery aiming at preserving fertility
Fertility-sparing surgery may be an option for selected patients who wish to retain the ability
to achieve a pregnancy. In many cases, pregnancies will occur spontaneously, nevertheless,
causes of subfertility may be present in some patients, and a number of those may further
require assisted reproduction treatments [5]. In gynecologic and urologic oncologic surgery,
there has been a gradual development of fertility-sparing surgery aiming at preserving
reproductive organs without compromising survival. Indications for fertility-sparing surgery
include, in general, a well-differentiated low-grade tumor in its early stages or with low
malignant potential.
3.2. Fertility sparing surgery in female patients
Table 1 presents a compilation of current data on fertility sparing surgery for young female
patients with gynaecological cancer. In cases of selected ovarian tumors i.e. borderline tumors,
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young female patients may be offered a single oophorectomy aiming at preserving the uterus
and the contralateral ovary[6].
Diagnosis Type of surgery Description Obstetric outcome Oncologic outcome
Cervical cancer stage
IA1,1A2,1B1
Radical vaginal
trachelectomy
Laparoscopic pelvic
lymphadenectomy. Vaginal
resection of the cervix and
surrounding parametria
keeping the corpus of the
uterus and the ovaries intact
Spontaneous
pregnancies
described in up to
70%. Risk of second
trimester pregnancy
loss and preterm
delivery
Rates of recurrence and
mortality are
comparable to those
described for similar
cases treated by means
of radical hysterectomy
or radiation therapy
Borderline ovarian
tumors FIGO stage I
Unilateral
oophorectomy
Removal of the affected
ovary only, keeping in place
the unaffected one and the
uterus
Pregnancies have
been reported and
favorable obstetric
outcome
Oncologic outcome is
comparable with the
more radical approach
of removing both
ovaries and the uterus.
Recurrence 0-20% vs
12-58% when only
cystectomy was
performed
Ovarian epithelial
cancer stage I, grade 1
Unilateral
oophorectomy
Removal of the affected
ovary only, keeping in place
the unaffected one and the
uterus
Pregnancies have
been reported and
favorable obstetric
outcome
7% recurrence of the
ovarian malignancy and
5% deaths
Malignant ovarian
germ cell tumors/sex
cord stromal tumors
Unilateral
oophorectomy
Removal of the affected
ovary only
Pregnancies have
been reported and
favorable obstetric
outcome
Risk of recurrence
similar to historical
controls
Endometrial
adenocarcinoma
Grade 1, stage 1A
(without myometrial
or cervical invasion)
Hormonal
treatment with
progestational
agents for 6
months
Follow-up with endometrial
biopsies every 3 months
Pregnancies have
been reported
Recurrence rate
30-40%. Five percent
recurrence during
progesterone treatment
Table 1. Fertility-sparing interventions in female patients. Reprinted, with permission from Rodriguez-Macias
Wallberg et al, J Pediatric Blood & Cancer, 2009, Ref [6].
The most established surgical procedure for fertility preservation of women is the radical
trachelectomy described first by Dargent in 1994 [7]. It is currently offered in cases of invasive
cervical cancer in early stages to patients interested in preserving fertility. About 500 cases
have been reported worldwide, most of them in European countries, Japan, U.S.A, Canada
and China [8-12].
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The global utilization of fertility-sparing surgery in female patients is currently unknown. A
recent European study collecting data from several countries demonstrated a low incidence
of those procedures and it raised concerns on the need to centralize fertility sparing treatments
of gynaecological cancer at accredited units, to ensure a sufficient number of patients at each
center aiming at maintaining thus healthcare quality [13].
3.3. Cervical cancer and fertility sparing surgery during pregnancy
In pregnant women, the gynaecological cancer most commonly diagnosed is also the cancer
of the cervix, usually detected at an early stage in those patients. The treatment of pregnant
women should be established in the same way as in non-pregnant patients, based on the stage
of the disease according to the International Federation of Gynecology (FIGO). Nevertheless,
individualization of the treatment should be considered based on the desire to continue the
pregnancy, the gestational age and the risks of modifying or delaying cancer treatment during
the pregnancy. Clinical practice guidelines by the European Society for Medical Oncology
ESMO are available on this respect [14]. Both abdominal radical trachelectomy [15] and vaginal
trachelectomy [16] with lymphadenectomies have been reported during pregnancy to preserve
an ongoing pregnancy and female fertility.
3.4. Fertility sparing surgery in males
In men, a partial orchidectomy has become an established method to preserve hormonal and
sperm production in carefully selected patients. This method, originally developed for
treatment of benign teratomas in prepubertal patients, has shown good results when adopted
for treatment of testicular malignancies in adults [17]. Data from The German Testicular Cancer
Study Group reported a 98.6% disease-free survival rate at 7 years follow-up after conservative
surgery of tumors <2 cm [18].
4. Radiotherapy treatments and their impact in reproductive health
Radiation therapy is a component of curative therapy for a number of diseases, including those
presenting frequently in young patients such as breast cancer, Hodgkin's disease, head and
neck cancer and gynecologic cancers. It is often indicated for the treatment of prostate cancer
as well.
It is known that cancer cells present with defects in their ability to repair sub-lethal DNA
whereas normal cells have the ability to recover. Although radiation therapy is aimed to a loco-
regional application and although cancer cells are the target, radiation may also induce damage
to normal cells in the tissues.
The response to radiation therapy depends on various factors such as the phase of cell cycle
the cells are (cells in late G1 and S are more resistant), the degree of cell ability to repair the
DNA damage and other factors such as hypoxia (hypoxic cells are more resistant), tumor mass
and growth fraction. Non-dividing cells are more resistant than dividing cells.
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Except for the bone marrow, the most sensitive organs to radiation therapy in the body are the
gonads, both the male testis and the female ovary. The extent of damage in the female and
male gonads depends on the dose, fractionation schedule and irradiation field [19] [20].
Radiation therapy can be administered as teletherapy, which aims at treating a large volume
of tissue. For small volumes of tissue, such as in the case of cervix cancer in the female, radiation
therapy can be administered in encapsulated sources of radiation that can be implanted
directly into or adjacent to tumor tissue.
Whenever female reproductive organs are involved in the irradiated field, i.e., the ovaries, the
uterus and the vagina may be compromised and damaged by direct irradiation. Scattered
radiation may also damage reproductive organs. In the female, radiation therapy results in
dose-related damage of the gonads by the destruction of primordial follicles, which constitute
the nonrenewable follicle pool. In women, the degree and persistence of the damage is also
influenced by age at the time of exposure to radiotherapy and due to a reduced reserve of
primordial follicles in older women, the number of follicles remaining may be also be reduced
at older ages [21]. Table 2 presents a compilation of current knowledge on the impact of
radiation doses and age at radiotherapy in male and female gonadal function [22]. In general,
a dose of about 2 Gy applied to the gonadal area destroys up to 50 % of the ovarian follicle
reserve. In pediatric patients, failure in pubertal development may be the first sign of gonadal
failure in both sexes. Total body irradiation (TBI) given in conjunction with myeloablative
conditioning prior to bone marrow transplantation is one of the most toxic treatments for the
gonads and it is highly related to gonadal failure in both sexes [23] [24].
High risk of prolonged azoospermia in men or amenorrhea in women
Total Body Irradiation (TBI) for bone marrow transplant/stem cell transplant (9,15,16)
Testicular radiation dose "/>2.5 Gy in adult men (9,17)
Testicular radiation dose ≥ 6 Gy in pre-pubertal boys (18,19)
Pelvic or whole abdominal radiation dose ≥ 6 Gy in adult women (20,21,22)
Pelvic or whole abdominal radiation dose ≥ 10 Gy in post-pubertal girls (21,22,23,24)
Pelvic radiation or whole abdominal dose ≥ 15 Gy in pre-pubertal girls (21,22,23,24)
Intermediate risk
Testicular radiation dose 1-6 Gy from scattered pelvic or abdominal radiation (13,16)
Pelvic or whole abdominal radiation dose 5-10 Gy in post-pubertal girls (21,24)
Pelvic or whole abdominal radiation dose 10-15 Gy in pre-pubertal girls (21,22,24)
Craniospinal radiotherapy dose ≥ 25 Gy (14)
Table 2. Radiotherapy protocols with high or intermediate impact on ovarian and testicular function. Reprinted, with
permission from Rodriguez-Wallberg and Oktay, J Ped Hematol Oncol, 2010, Ref [22].
In men, the gonadal stem cells responsible for the continual differentiation and production of
mature spermatozoa, the spermatogoniae, are extremely sensitive to radiation. The Leydig
cells, which are responsible for the hormonal production of testosterone, are on the contrary
more resistant to radiotherapy and adult patients may thus preserve hormonal production
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although becoming infertile. In prepubertal boys, the sensitivity to radiation therapy of Leydig
cells is greater than that of older males at very high doses [25]. Prepubertal patients may retain
Leydig cell function after radiation therapy during childhood and in those cases they will
present with normal pubertal development and well-preserved sexual function later in life.
Nevertheless, most of those patients present at adulthood with reduced testicular size,
impaired spermatogenesis and infertility.
4.1. Gonadal shielding and ovarian transposition
The standard medical procedure currently offered to reduce scatter radiation to reproductive
organs and preserve fertility in male and female patients, both adult and prepubertal, is the
use of shielding. When shielding of the gonadal area is not possible, the surgical fixation of
the ovaries in females far from the radiation field known as oophoropexy (ovarian transposi‐
tion) may be considered. It is estimated that this procedure significantly reduces the risk of
ovarian failure by about 50% and those patients may retain some menstrual function and
fertility [26]. Scattered radiation and damage of the blood vessels that supply the ovaries are
related to the failure of this procedure [26].
4.2. Radiotherapy of the uterus
Radiotherapy of the uterus in young women and girls has shown to induce tissue fibrosis,
restricted uterine capacity, restricted blood flow and impaired uterine growth during preg‐
nancy, as shown by follow-up of cancer survivors [27] [28]. The uterine damage seems to be
more pronounced in the youngest patients at the time of radiotherapy. As a consequence,
radiotherapy-treated female patients present with a high risk of unfavorable pregnancy
outcomes such as spontaneous abortion, premature labor and low birth weight offspring [27]
[28]. Irradiation of the vagina is related to fertility and sexual issues due to loss of lubrication,
anatomical impairments and in some cases vaginal stenosis.
4.3. Cranial irradiation and hormonal dysfunction
Cranial irradiation may induce disruption of the hypothalamic-pituitary-gonadal axis, which
is a recognized potential complication that can lead to infertility in both female and male
patients. Follow-up of female patients treated for brain tumors with cranial irradiation post-
and pre-pubertally has evidenced a high incidence of primary hypothalamic and pituitary
dysfunction with consecuent disturbance in gonadotropin secretion. In some cases, precocious
puberty may also be induced by cranial irradiation in childhood, which has been attributed to
cortical disruption and loss of inhibition by the hypothalamus.
5. Impact of chemotherapy in reproductive health
Chemotherapy given as only treatment may be curative for a series of cancer presenting in
young adults and children. In a vast majority of cancer treatments, chemotherapy proto‐
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cols  combine  several  agents  and  there  is  a  possibility  of  a  synergistic  gonadotoxic  ef‐
fect[29]. In the female, primordial ovarian follicles including their oocytes and granulosa
cells are particularly sensitive to alkylating agents, which induce apoptosis, as demonstrat‐
ed in vitro [26], and in vivo using human ovarian tissue xenotransplanted in SCID mouse
[30]. Ovarian failure is thus common after alkylating treatment [22].
Because of a high ovarian reserve with high numbers of follicles in young women, the risk of
developing ovarian failure and permanent infertility after a cancer treatment is lower in
younger than in older women [21]. Younger patients at the time of cancer treatment have thus
a higher chance of recovering ovarian function following chemotherapy, nevertheless their
fertility window might be reduced, and they should be recommended not to delay childbearing
for too long [31].
5.1. Clinical evaluation of ovarian reserve
The development of  amenorrhea should be considered unfavorable as it  may be due to
permanent  gonadal  failure.  On  the  other  hand,  the  presence  of  cycles  should  not  be
interpreted as proof of fertility. In the clinical setting, a gynecological examination includ‐
ing ultrasonography and estimation of antral follicle counts together with the determina‐
tion of hormones such as follicle-stimulating hormone (FSH) and estradiol, inhibin and anti-
mullerian hormone (AMH), may help the clinician in evaluating patient’s remaining ovarian
reserve  after  a  cancer  treatment  and  providing  counseling  on  her  chances  to  obtain  a
pregnancy.
5.2. Conception following chemotherapy
Due to  toxicity  of  cancer  treatments  on growing oocytes,  patients  should be advised to
avoid conception in the 6 -12 month period immediately following completion of chemother‐
apy treatment [32]. There is a high risk of teratogenesis during or immediately following
chemotherapy, nevertheless DNA integrity has shown to return over time after a cancer
treatment and thus no increase in childhood malignancies or genetic malformations have
been shown in a large follow-up of more than 4000 children of cancer survivors [33].
5.3. Chemotherapy in males
In male patients, prepubertal status does not provide protection from gonadal damage and
alkylating agents at  high doses induce germ cell  injury although Leydig cell  function is
commonly  preserved  [29].  Because  most  chemotherapy  agents  are  given  as  part  of  a
combination regimen, it has been difficult to quantify the gonadotoxicty of individual drugs.
Table 3 summarizes the gonadotoxic impact of chemotherapy agents on the female ovary and
male testis.
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6. Options to preserve fertility by using cryopreservation methods
In 2006, an expert panel commissioned by the American Society of Clinical Oncology ASCO
published guidelines for fertility preservation for male and female patients [26]. Established
cryopreservation methods for fertility preservation available for adult female and male cancer
patients before starting cancer treatments included sperm freezing for male patients and
embryo cryopreservation following ovarian stimulation with gonadotropins and In Vitro
Fertilization, IVF for females. All remaining options were still considered experimental at that
time and they included the freezing of unfertilized oocytes for adult women and the cryopre‐
servation of gonadal tissue, ovarian or testicular, both methods still under development which
constitute the only options that can be offered to pre-pubertal children (Figure 1).
Recently, by the end of 2012, the methods for cryopreservation of oocytes by vitrification
techniques have markedly improved and thus freezing of unfertilized eggs is currently
becoming an established clinical option for female patients.
High risk of prolonged azoospermia in men or amenorrhea in women
Cyclophosphamide
Ifosphamide
Melphalan
Busulfan
Nitrogen mustard
Procarbazine
Chlorambucil
Intermediate risk
Cisplatin with low cumulative dose
Carboplatin with low cumulative dose
Adriamycin
Low risk
Treatment protocols for Hodgkin lymphoma without alkylating agents
Bleomycin
Actinomycin D
Vincristine
Methotrexate
5 fluorouracil
Table 3. Chemotherapy agents with high or intermediate gonadotoxic impact in women and men
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6.1. Sperm banking for male patients
As many children are born after fertility treatments using frozen-thawed sperm, the cryopreser‐
vation of ejaculated semen is regarded as an established fertility preservation method in adult
patients and pubertal boys. Although spermatogenesis starts in the pre-pubertal period and
mature spermatozoa can be found at a Tanner III stage with a testis volume above 5 ml, sperma‐
tozoa production is generally effective only at the age of 13-14 years [33]. Sperm cryopreserva‐
tion has been reported in adolescent patients from the age of 13 years with a high prevalence of
normal sperm counts and semen volumes [34] [35]. Traditionally, sperm banking by cryopreser‐
vation of at least three semen samples with an abstinence period of at least 48 hours in between
the samples has been recommended for adult males desiring to preserve their fertility [36].
In the situation of ejaculation failure, the search for spermatozoa in a urine sample could be
proposed. When failure in obtaining a semen sample in young men and adolescents, a
testicular sperm extraction TESE can be performed to retrieve spermatozoa [35]. Other
methods described to retrieve spermatozoa in adolescents include penile vibratory stimulation
and electro ejaculation.
6.2. Cryopreservation of embryos or oocytes after controlled ovarian stimulation in females
Adult women wishing to preserve fertility may undergo controlled ovulation stimulation with
gonadotropins, for retrieval of matured oocytes and egg freezing, or, if the woman wishes, for
in vitro fertilization (IVF) of the retrieved eggs and freezing of embryos. In general, controlled
Figure 1. Strategies for fertility preservation in males and females
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ovarian stimulation with gonadotropins for IVF may require only two weeks to achieve, as it
has been shown that a random-start in the stimulation cycle, independently of cycle day, does
not have a negative impact on the number and quality of oocytes retrieved.
Oocyte retrieval is undertaken usually by vaginal ultrasound assistance under sedation or
general anaesthesia. Fertilization of the oocytes for embryo cryopreservation has traditionally
been offered to woman having a partner. Transfer of frozen/thawed embryos today is a clinical
routine in fertility clinics worldwide and it has been used for over 25 years. Intact embryos
after thawing have similar implantation potential as fresh embryos and this treatment can lead
to a 59% pregnancy rate and a 26% live birth rate [37].
Freezing unfertilized oocytes aiming at later thawing and fertilizing them by IVF is also a
promising option to preserve fertility today. As the methods for cryopreservation of eggs have
notably developed in recent years with the development of vitrification techniques, improving
success in oocyte survival and fertilization rates has been achieved, approaching that of fresh
oocytes. Worldwide, an increasing number of pregnancies and children born after fertilization
of frozen-thawn oocytes has been reported and although overall pregnancy rates are still relatively
lower than those with embryo freezing [38-40], pregnancy rates and livebirths after thawing and
fertilizing frozen eggs are currently reaching those obtained after embryo cryopreservation [41].
6.3. Ovarian stimulation using aromatase inhibitors to maintain low systemic estradiol
levels in case of breast cancer
Ovarian stimulation with gonadotropins before egg retrieval aims at obtaining more than one
oocyte per cycle and it is a key component of the success of IVF.
In women with an estrogen-sensitive tumor, the elevation of circulating estradiol levels during
ovulation stimulation is undesirable and it has been regarded as potentially harmful. There‐
fore, hormone positive breast cancer patients have been largely excluded of the option to
preserve fertility aiming at freezing eggs or embryos [42].
Alternative protocols, including natural cycle IVF (without hormone stimulation) or inducing
ovulation by using Selective Estrogen Receptor Modulators (SERMs) and aromatase inhibitors
alone or in combination with gonadotropins have been proposed, as they might be potentially
safer. Natural cycle IVF gives only one oocyte or embryo per cycle and this treatment protocol
has a high rate of cycle cancellation.
Both tamoxifen and letrozole can be administered alone or alongside with gonadotropins to
increase the number of oocytes yielded for cryopreservation. Stimulation protocols using
letrozole alongside with gonadotropins have shown to be most effective resulting in higher
number of oocytes obtained and fertilized when compared to tamoxifen protocols [43]. The
short-term follow-up of breast cancer patients having undergone ovarian stimulation with
letrozole for fertility preservation has not shown any detrimental effects on survival [44].
Although aromatase inhibitors are contraindicated during pregnancy, data indicate that
fertility treatments with letrozole are safe and the use of letrozole before conception does not
induce any increased risks for the fetus [45]. Letrozole is currently used in the treatment of
anovulatory infertility in many countries.
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6.4. Cryopreservation of immature oocytes obtained without hormonal stimulation
Freezing immature oocytes is also an option for female fertility preservation in case of patients
having a contraindication for hormonal stimulation or when there is not time available for
stimulation. The oocytes are retrieved in the natural cycle and frozen at an immature stage or
after maturation in vitro (IVM) [46]. Immature oocytes survive cryopreservation better than
mature metaphase II oocytes [47]. After thawing they can be matured in vitro and fertilized.
In vitro maturation of oocytes is at an experimental stage and needs further development. Only
few fertility centers worldwide offer treatments using this technique.
6.5. Ovarian tissue freezing for prepubertal and adult patients
As the vast majority of eggs making up the ovarian reserve are within primordial follicles in
the ovarian cortex, small cortical ovarian biopsies may provide a high number of eggs to be
preserved. This procedure is usually performed by laparoscopy, can be planned immediately
after the diagnosis of malignant disease and does not require hormonal stimulation. In cases
when the patient needs to undergo abdominal surgery for the treatment of cancer, the ovarian
tissue can be harvested during the same surgical procedure. Although it is preferable to carry
out cryopreservation of ovarian tissue before a gonadotoxic treatment, young women,
adolescents and girls have normally an abundant number of primordial follicles in their ovaries
and attempts to harvest ovarian tissue for cryopreservation may still be worthwhile after the
first courses of chemotherapy, if the procedure was not possible before [6].
Cryopreservation of ovarian tissue is the only option in prepubertal girls, as sexual maturity
is not required. As this procedure does not cause any significant delay to initiation of cancer
treatment and it does not require ovarian stimulation, some adult female patients also prefer
to preserve fertility by this method.
6.6. Ovarian tissue transplantation
Transplantation of frozen-thawn ovarian cortex has shown to be a new promising method for
recovery of ovarian function [48] and in some cases sufficient to restore fertility [49-51]. Ovarian
tissue can be transplanted orthotopically, i.e. at the anatomical intrapelvic ovarian site or
heterotopically, i.e. at other places including extrapelvic sites [52, 53].
There have been hundreds of patients undergoing ovarian tissue freezing but only a small
percentage of these have returned for ovarian transplantation.
Autotransplantation is only possible if absence of malignant cells in the graft is confirmed.
Methods for detection of cancer cells in the ovarian tissue of patients having suffered from
hematological malignancies are under development including immunohistochemistry or the
polymerase chain reaction applied to the tissue [54]. The investigation of residual malignant
cells in the ovarian tissue may also be performed by xeno-transplantation to immunodeficient
SCID mouse. Autotransplantation of ovarian tissue in patients having suffered from systemic
hematological malignancies is not recommended due to the high risk of retransmission of
malignancy and only patients with cancer diagnosis associated with a negligible or no risk of
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ovarian compromise should be considered for future autotransplantation [55]. Ovarian tissue
cryopreservation and transplantation has shown not to interfere with proper genomic
imprinting in mice pups [56] but additional studies in other animal models are needed.
6.7. In vitro culture of ovarian follicles
Although many improvements have been reported on the in vitro culture of follicles at early
stages aiming at developing them into competent mature follicles, those methods are still on
development [57-59]. Follicles cultured isolated or within a piece of thawed tissue will be the
option for patients with hematological and ovarian malignancies. The normality of imprinted
genes of cryobanked oocytes cultured and matured in vitro has yet to be verified experimentally.
6.8. Testicular tissue cryopreservation
This technique involves removal of testicular tissue from the male patient before cytotoxic
therapy is initiated. In prepubertal boys, as there is absence of spermatozoa and spermatids,
studies have been going on to cryopreserve the testicular totipotent precursors, i.e. the
spermatogonial stem cells. Success has been reported in cryopreservation methods of testicular
tissue [60] but more research is still needed in how to use the frozen-thawed tissue and obtain
mature spermatozoa in vitro. Research suggests that in vitro spermatogenesis is likely to be
the safest option for boys suffering from haematological malignancies, which might be re-
transmitted by retransplantation, but this technique is still to be fully developed [61]. Although
there are promising results in experimental animal studies of autologous retransplantation of
spermatogonial stem cells showing re-colonization of seminiferous tubules generating
complete spermatogenesis and mature germ cells and thus restoring natural fertility, the
technique is still experimental in humans [61].
Cryopreservation of gonadal tissue offers hope to childhood cancer survivors, however it also
raises several medical and ethical questions. Experimental methods for fertility preservation
should only be offered to patients at specialized centers working with ethics board-approved
research protocols and only in case when the recognized risks associated to the procedure are
minimal.
6.9. Ovarian suppression to prevent gonadal damage
It has been hypothesized that suppressing the gonadal function transiently during chemo‐
therapy could prevent ovarian follicle destruction in female patients by maintaining the
follicles dormant. However, the pool of primordial follicles is normally non-proliferating.
Those follicles lack FSH receptors [62] and their initial recruitment is not controlled by
gonadotropins [63], therefore hormonal manipulation by suppressing gonadotropin release is
not likely to affect them [64]. The vast majority of available studies having investigating
gonadal protection by gonadotropin-releasing hormone analogues (GnRHa) agonists or
antagonists during chemotherapy in females have been small, retrospective and uncontrolled.
A significant number of those studies had used resumption of menses as a surrogate marker
for fertility and many of them had reported higher frequency of resumption of menses in
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women having received GnRHa but none has demonstrated a beneficial effect regarding
fertility recovery. Although data indicate that infertility is increased after a chemotherapy
treatment, even if menstrual cycles are resumed [65], studies suggesting a beneficial effect of
GnRHa co-treatment on preserving menstruation have had a great impact in the medical
community and the empirical use of GnRHa for ovarian protection during chemotherapy is
currently widely spread [26].
7. Counseling and prompt referal increase the chances to preserve fertility
Despite the fact that fertility issues are recognized in young people with cancer, health care
professionals still report never referring cancer patients of reproductive age to a reproductive
specialists for fertility preservation, indicating that many patients still do not receive adequate
and timely information [66] [67]. This contrasts to data indicating that approximately three out
of four cancer patients younger than 35 years and childless at the time of cancer treatment may
be interested in having children in the future [2]. Because incidence of most cancers increases
with age, the trend of delaying childbearing in Western societies will naturally result in more
female cancer patients interested in fertility preservation.
In despite of this, recent data indicate that female cancer patients are still poorly informed on
fertility threats of cancer treatment and options to preserve fertility in comparison with their
gender counterparts. A recent Swedish survey found that less than half of female patients
recalled having received appropriate information on reproductive threats of cancer therapy
whereas 80% of male patients recalled having had an appropriate discussion [67]. Only a small
number of female patients used fertility preservation methods compared to a rate >70% of
sperm freezing in male patients in that study. Urgency to start cancer treatment and lack of
appropriate time, lack of knowledge on fertility preservation and awareness of the costs of
assisted reproduction methods are recognized barriers to counseling and referring patients to
fertility preservation [68].
8. Conclusion
Infertility due to gonadal failure is one of the major consequences of cancer therapy, particu‐
larly in patients who receive aggressive chemotherapy and/or radiotherapy treatment. Many
surveys of cancer survivors have found that those patients are at increased risk of emotional
distress if they become infertile as a result of their treatment. Evidence suggests that long-term
survival after treatment for cancer during childhood is associated with increased risk of
impaired quality of life and higher frequency of psychosocial problems often related to
infertility issues. Adolescent cancer survivors have increased anxieties about body image and
dating, and pediatric cancer survivors are less likely to marry than matched controls. Although
cancer survivors can become parents by adoption or gamete donation, most would prefer to
have biological parenthood and biologically related children.
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Oncologists should thus be prepared to discuss the negative impact of cancer therapy on
reproductive potential with their patients in the same way as any other risks of cancer
treatment are discussed. Furthermore, patients interested in fertility preservation should be
promptly referred to a reproductive medicine expert to offer timely and appropriate counsel‐
ing and improve success of fertility preservation. Close collaboration between the oncology
team and the reproductive endocrinologists should be encouraged.
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